# US Blood Grouping Reagents Market

> US Blood Grouping Reagents Market Research Report: Size, Share, Trend Analysis By Product (Consumables, Instruments), By Technique (PCR-based and Microarray Techniques, Assay-Based Techniques, Massively Parallel Sequencing Techniques, Serology), By Test Type (Blood Group and Phenotypes, Antibody Screening, Crossmatching Tests, Antibody Identification, Coombs’s Test, Antigen Typing) and By End Users (Hospitals, Blood Banks, Clinical Laboratories) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 7.51%
- **2024:** $ 0.58 Million
- **2025:** $ 0.63 Million
- **2035:** $ 1.3 Million
- **Key Players:** Abbott Laboratories (US), Thermo Fisher Scientific (US), Siemens Healthineers (DE), Bio-Rad Laboratories (US), Ortho Clinical Diagnostics (US), Grifols (ES), Beckman Coulter (US), Merck KGaA (DE), F. Hoffmann-La Roche (CH)

**Report ID:** MRFR/HC/12347-HCR · **Pages:** 100 · **Author:** Vikita Thakur & Garvit Vyas · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-blood-grouping-reagents-market-13872

---

## Market Summary

## **US Blood Grouping Reagents Market Overview**

**As per MRFR analysis, the US Blood Grouping Reagents Market Size was estimated at 0.08 (USD Million) in 2023. The US Blood Grouping Reagents Market Industry is expected to grow from 0.88(USD Million) in 2024 to 1.95 (USD Million) by 2035. The US Blood Grouping Reagents Market CAGR (growth rate) is expected to be around 7.501% during the forecast period (2025 - 2035).**

### **Key Highlights and Growth Projections**

The US Blood Grouping Reagents Market is experiencing several significant trends driven by factors such as technological advancements, increased blood donation awareness, and the rising incidence of blood transfusions. The demand for precise blood typing is essential for ensuring compatibility in blood transfusions and organ transplants, leading to innovations in reagent formulations and testing methods. With the growing focus on patient safety and regulatory compliance, laboratories and healthcare institutions are increasingly adopting advanced reagents that offer higher accuracy and faster results.

Additionally, there is a notable trend towards the automation of blood grouping processes, which improves efficiency and reduces human error. This shift is facilitated by the integration of artificial intelligence and machine learning technologies into testing systems, streamlining workflows in clinical laboratories across the US. Market players are exploring opportunities to launch more reliable and cost-effective reagents that cater to a variety of blood grouping technologies, further bolstering the market's growth potential.

Opportunities in the US [Blood Grouping Reagents](../../../reports/blood-grouping-reagents-market-10725) Market can also be attributed to the rise in research activities focused on hematology. Academic and clinical laboratories are increasingly engaged in studies that emphasize better blood management systems and the development of new blood typing methodologies. These changes align with the needs of an aging population and emphasize the importance of efficient blood banking and transfusion services. With the support of government initiatives aimed at enhancing blood donation drives and improving healthcare infrastructure, the market stands to benefit from future growth.

Overall, the convergence of technology, increasing awareness of blood donation, and a focus on precision in transfusion medicine mark the current landscape of the US Blood Grouping Reagents Market.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **US Blood Grouping Reagents Market Drivers**

### **Rising Incidence of Blood Transfusions and Surgical Procedures**

The demand for blood grouping reagents in the US Blood Grouping Reagents Market Industry is significantly driven by the increase in blood transfusions and surgical procedures. The American Hospital Association reported that there were approximately 15 million blood transfusions in the United States annually. This growth is largely attributed to an increase in surgical interventions, trauma cases, and cancer treatments requiring frequent blood transfusions.

Notably, the Centers for Disease Control and Prevention projected a growth in surgical procedures, supporting the perception that the population's aging demographic will lead to greater demands for such treatments. Consequently, as the need for safe and compatible blood products rises, the US Blood Grouping Reagents Market industry is poised for substantial growth as it plays a critical role in ensuring patient safety and optimal outcomes in transfusions.

### **Technological Advancements in Blood Grouping Techniques**

Technological innovations in blood grouping reagents and related methodologies are another significant driver of the US Blood Grouping Reagents Market industry. The introduction of automated blood grouping systems and advanced molecular techniques has not only improved accuracy but also enhanced the efficiency of blood transfusion practices. According to the Food and Drug Administration, the adoption of next-generation sequencing technologies has led to increased safety and precision in blood matching, thereby reducing the risk of transfusion reactions.

This advancement is crucial, as healthcare facilities are increasingly investing in new technologies to improve patient care, which directly impacts the growth potential of the US Blood Grouping Reagents Market.

### **Growing Prevalence of Blood Disorders**

The rising prevalence of blood disorders, such as hemophilia, thalassemia, and sickle cell anemia, significantly influences the US Blood Grouping Reagents Market industry. The National Institutes of Health reported that around 1 in every 400,000 individuals in the United States is born with hemophilia, a serious condition requiring regular blood transfusions and monitoring for adequate treatment. This increasing patient population underscores the need for reliable blood grouping reagents to ensure appropriate care and treatment protocols.

Additionally, awareness programs and advocacy from organizations like the National Hemophilia Foundation encourage early diagnosis and treatment, effectively increasing the demand for blood grouping reagents.

## **US Blood Grouping Reagents Market Segment Insights**

### **Blood Grouping Reagents Market Product Insights**

The US Blood Grouping Reagents Market is characterized by a distinct focus on the Product segment, primarily encompassing Consumables and Instruments. In the healthcare landscape, these categories play vital roles in blood testing laboratories, hospitals, and other medical facilities, bolstering the efforts in diagnostic accuracy and patient safety. Consumables represent a significant aspect of this segment, as they include chemical reagents, disposables, and related accessories that are essential for the accurate and efficient classification of blood types.

The increasing prevalence of blood transfusion procedures and the rising demand for safe blood components have heightened the necessity for reliable consumables. Instruments, on the other hand, consist of high-tech analyzers and diagnostic equipment that streamline the blood grouping process, making it faster and more reliable. The advancement of technology in this field fosters innovation in instrument design and functionality, enhancing the overall efficiency in blood diagnostics.

Additionally, the US is witnessing a rise in healthcare investments, leading to the modernization of medical facilities and an upgrade of existing diagnostic equipment, which is likely to further bolster the demand for these Products. Moreover, as the population ages and chronic diseases rise, the need for effective blood grouping and transfusion services is expected to contribute to the positive growth trajectory of the US Blood Grouping Reagents Market.

The segmentation of the market into Consumables and Instruments allows for a nuanced understanding of trends and consumer behavior, with each area presenting unique challenges and opportunities. The regulatory environment also plays a crucial role, as policies aimed at improving blood safety and quality standards encourage the use of advanced reagents and instruments. As such, both Consumables and Instruments segments not only address current healthcare needs but also set the stage for future innovations and developments in the US Blood Grouping Reagents Market landscape.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Blood Grouping Reagents Market Technique Insights**

In the US Blood Grouping Reagents Market, the Technique segment plays a crucial role in determining the efficiency and accuracy of blood grouping processes. The market encompasses various methodologies, with PCR-based and Microarray Techniques gaining popularity due to their precision and reliability in genetic analysis. Assay-Based Techniques are widely used for their ability to provide rapid results, making them significant in clinical settings where timely decisions are critical.

Massively Parallel Sequencing Techniques represent a breakthrough in high-throughput testing, enabling extensive genetic information to be gathered from a single test, which is vital for understanding individual blood types and compatibility in transfusions. Serology remains a cornerstone of blood grouping, leveraging antibody-antigen reactions to identify blood types efficiently, contributing to its dominance in transfusion medicine. The diversity within the Technique segment reflects ongoing advancements and innovations that enhance diagnostics and therapeutic strategies in transfusion practices and related healthcare services, ultimately driving growth in the US Blood Grouping Reagents Market.

### **Blood Grouping Reagents Market Test Type Insights**

The Test Type segment within the US Blood Grouping Reagents Market plays a critical role in hematology and transfusion medicine, driving advancements in patient care and safety. The demand for Blood Group and Phenotypes testing is significant, as accurate blood typing is essential for safe blood transfusions and organ transplants. Similarly, Antibody Screening is vital for identifying any unexpected antibodies that may cause adverse reactions during transfusions.

Crossmatching Tests are crucial in matching donors with recipients, minimizing transfusion-related complications and ensuring successful transfusions. Antibody Identification further aids in determining specific antibodies present in a patient's serum, which is paramount for effective treatment. The Coombs's Test, essential for identifying autoimmune hemolytic anemia, underscores its importance in the diagnostic landscape.

Meanwhile, Antigen Typing is becoming increasingly vital, particularly in personalized medicine, to provide targeted therapies. This diverse range of testing options reflects the growing complexity and specialization in the US Blood Grouping Reagents Market, where technological advancements continue to enhance diagnostic accuracy and efficiency.

### **Blood Grouping Reagents Market End User Insights**

The US Blood Grouping Reagents Market, particularly within the End User segment, encompasses critical entities such as hospitals, blood banks, and clinical laboratories, which are pivotal to ensuring safe blood transfusions and effective disease diagnosis. Hospitals represent a substantial portion of the market, as they require reliable and accurate blood grouping reagents to provide timely patient care and manage blood transfusions, thus driving a significant demand for these products.

Blood banks play an essential role in blood collection, storage, and distribution, necessitating a continuous supply of high-quality reagents to assure the compatibility and safety of blood units. Clinical laboratories also contribute to the market through rigorous testing protocols that help in disease management and health monitoring, relying heavily on advanced reagents for precise results.

Trends indicate an increasing need for automation and technological advancements in these facilities, further enhancing the complexity and demand for blood grouping reagents. Overall, the growth in the End User segment is influenced by factors such as rising healthcare expenditure, increasing prevalence of blood-related diseases, and the pressing need for efficient transfusion management systems across the US.

## **US Blood Grouping Reagents Market Key Players and Competitive Insights**

The US Blood Grouping Reagents Market represents a critical sector within the healthcare industry, characterized by its complexity and the essential role it plays in transfusion medicine and diagnostic testing. This market is influenced by a variety of factors including regulatory requirements, advancements in technology, and growing awareness of the importance of accurate blood grouping in patient care. The competitive landscape features a range of established players and emerging entities, all vying for market share by offering innovative products and superior services.

The ongoing research and development activities contribute to the enhanced capabilities of blood grouping reagents, driving competition and catering to the rising demand across healthcare settings, including hospitals, blood banks, and laboratories.

### **Eton Bioscience's Market Strategy**

Eton Bioscience has carved a niche in the US Blood Grouping Reagents Market through its focus on precision and reliability. The company has established a formidable presence by producing high-quality reagents that meet both regulatory standards and the specific needs of healthcare providers. Eton Bioscience emphasizes innovation in its product offerings, enhancing their efficiency and effectiveness in blood typing procedures.

Their strengths lie in their robust distribution network, comprising key partnerships that allow for widespread availability of products. Additionally, Eton Bioscience has a strong commitment to customer service and technical support, ensuring that clients receive the necessary assistance in utilizing their reagents, further solidifying their competitive position in the market.

### **Fujirebio's Diagnostic Solutions**

Fujirebio stands out in the US Blood Grouping Reagents Market with its comprehensive range of diagnostic solutions aimed at improving patient outcomes. The company has developed key products that are integral to the accurate identification of blood types, thereby facilitating safe transfusions and effective patient management. Fujirebio’s strength is amplified by its commitment to research and development, leading to continuous improvements in the accuracy and reliability of their reagents.

The company has also strategically engaged in mergers and acquisitions to strengthen its portfolio and expand its market reach within the US. By fostering collaborations with various healthcare institutions, Fujirebio enhances its service offerings and positions itself as a leader in the blood grouping reagents space, effectively catering to the demands of the evolving healthcare landscape.

### **Key Companies in the US Blood Grouping Reagents Market Include**

#### **Leading Market Participants**

## **US Blood Grouping Reagents Market Industry Developments**

The US Blood Grouping Reagents Market has seen significant developments recently, with companies such as Abbott Laboratories, Grifols, and Siemens Healthineers advancing their product lines to enhance blood compatibility testing. In September 2023, Eton Bioscience launched a new line of reagents aimed at improving efficiency in blood type determination, reflecting a broader trend towards automation and rapid testing in laboratories. Additionally, BioRad Laboratories and Thermo Fisher Scientific are collaborating on innovative solutions to streamline blood grouping processes.

In terms of mergers and acquisitions, Beckman Coulter's acquisition of a smaller diagnostics firm in August 2023 to expand its reagent offerings marks a notable trend in market consolidation driven by the demand for comprehensive testing solutions. Furthermore, the valuation of companies in this sector has improved markedly, with a growth projection supported by the rise in blood transfusion procedures and the increasing prevalence of blood-related disorders.

Recent statistics from the US Food and Drug Administration suggest a steady increase in the use of blood grouping reagents, further weighing in favor of sustained workforce investments and Research and Development efforts in the coming years, reflecting the robust market dynamics.

## **US Blood Grouping Reagents Market Segmentation Insights**

### **Blood Grouping Reagents Market Product Outlook**

### **Blood Grouping Reagents Market Technique Outlook**

### **Blood Grouping Reagents Market Test Type Outlook**

### **Blood Grouping Reagents Market End User Outlook**

- Hospitals
- Blood Banks
- Clinical Laboratories

## Market Drivers

### Rising Prevalence of Blood Disorders

The increasing incidence of blood disorders in the US is a crucial driver for the blood grouping-reagents market. Conditions such as anemia, hemophilia, and sickle cell disease necessitate accurate blood typing and matching for effective treatment. According to the Centers for Disease Control and Prevention, approximately 3 million individuals in the US are affected by anemia alone. This growing patient population is likely to elevate the demand for blood grouping reagents, as healthcare providers require reliable and efficient testing solutions. Furthermore, advancements in diagnostic technologies may enhance the accuracy of blood typing, thereby fostering market growth. The blood grouping-reagents market is poised to benefit from this trend, as healthcare facilities increasingly invest in state-of-the-art reagents to ensure patient safety and effective treatment outcomes.

### Expansion of Healthcare Infrastructure

The ongoing expansion of healthcare infrastructure in the US significantly impacts the blood grouping-reagents market. With the establishment of new hospitals, clinics, and diagnostic laboratories, the demand for blood grouping reagents is expected to rise. The American Hospital Association reported that there were over 6,200 hospitals in the US as of 2023, and this number continues to grow. Enhanced healthcare facilities are likely to adopt advanced blood grouping technologies, which could lead to increased reagent consumption. Additionally, the integration of blood grouping reagents into routine laboratory practices may further stimulate market growth. As the blood grouping-reagents market adapts to these infrastructural changes, it is anticipated that the availability and accessibility of these essential reagents will improve, ultimately benefiting patient care.

### Increased Focus on Blood Donation Drives

The heightened emphasis on blood donation drives in the US serves as a significant driver for the blood grouping-reagents market. Organizations such as the American Red Cross actively promote blood donation campaigns, which are crucial for maintaining adequate blood supplies. As more individuals donate blood, the need for accurate blood typing and matching becomes paramount. This trend is likely to increase the demand for blood grouping reagents, as healthcare providers require reliable testing solutions to ensure compatibility. The blood grouping-reagents market may experience growth as a result of these initiatives, with an anticipated rise in the volume of reagents utilized during blood donation events. Furthermore, educational campaigns aimed at raising awareness about the importance of blood donation could further bolster market demand.

### Technological Integration in Blood Testing

The integration of advanced technologies in blood testing is a pivotal driver for the blood grouping-reagents market. Innovations such as automated blood typing systems and molecular diagnostics are transforming traditional testing methods. These technologies enhance the accuracy and efficiency of blood grouping, which is essential for patient safety. The blood grouping-reagents market is likely to benefit from the adoption of these advanced systems, as healthcare facilities seek to improve their testing capabilities. Moreover, the increasing trend towards point-of-care testing may further drive the demand for rapid and reliable blood grouping reagents. As technology continues to evolve, the market is expected to witness a shift towards more sophisticated testing solutions, ultimately enhancing the overall quality of care.

### Growing Awareness of Blood Safety Standards

The rising awareness of blood safety standards among healthcare providers and patients is a significant driver for the blood grouping-reagents market. Regulatory bodies in the US emphasize the importance of adhering to stringent blood safety protocols to prevent transfusion-related complications. This heightened awareness is likely to lead to increased investments in high-quality blood grouping reagents, as healthcare facilities strive to comply with safety regulations. The blood grouping-reagents market may experience growth as hospitals and laboratories prioritize the use of reliable reagents to ensure patient safety. Furthermore, educational initiatives aimed at informing healthcare professionals about the latest blood safety standards could further stimulate demand for advanced blood grouping reagents, reinforcing the importance of quality in blood testing.

## Future Outlook

The [Blood Grouping Reagents Market](https://www.marketresearchfuture.com/reports/blood-grouping-reagents-market-10725) is projected to grow at 7.51% CAGR from 2025 to 2035, driven by technological advancements, increasing demand for blood transfusions, and rising awareness of blood safety.

**New opportunities:**

- Development of automated blood grouping systems for hospitals Expansion of e-commerce platforms for reagent distribution Partnerships with diagnostic labs for customized reagent solutions

By 2035, the market is expected to achieve robust growth, driven by innovation and strategic partnerships.

## Segment Insights

### By Product: Consumables (Largest) vs. Instruments (Fastest-Growing)

In the US blood grouping-reagents market, the market share is predominantly held by the consumables segment, which encompasses various reagents and testing supplies. This segment accounts for a substantial portion of the total market, indicating its importance and steady demand in blood grouping procedures across healthcare settings. Instruments, while a smaller segment in terms of current share, have been experiencing increasing adoption, particularly with advancements in technology and automation in laboratories.

The growth trends in this segment are largely driven by the rising number of blood donations and transfusions, resulting in higher demand for efficient and reliable testing methods. The instruments segment is anticipated to see the fastest growth due to technological innovations, such as automated blood grouping systems, which enhance accuracy and reduce turnaround time. Furthermore, the ongoing investments in healthcare infrastructure also support the expansion of both segments.

Consumables: Dominant vs. Instruments: Emerging

Consumables dominate the US blood grouping-reagents market due to their essential role in routine blood testing procedures. This segment includes a wide range of reagents, blood typing kits, and other supplies that are critical for accurate blood analysis. The steady demand is fueled by the regular need for transfusion services and compatibility testing in transfusion medicine. In contrast, the instruments segment is emerging rapidly, driven by innovative technologies that offer advanced features for efficiency and precision. Automated systems, which are becoming increasingly popular in laboratories, provide significant improvements in workflow and test accuracy. As healthcare facilities seek to enhance their diagnostic capabilities, the instruments segment is well-positioned for growth, complementing the established consumables market.

### By Technique: PCR-based and Microarray Technique (Largest) vs. Assay-Based Techniques (Fastest-Growing)

The market share of the various techniques in the US blood grouping-reagents market showcases diverse segments. Among these, the PCR-based and Microarray Technique holds the largest share, reflecting its widespread adoption due to accuracy and efficiency in blood grouping and typing. In contrast, Assay-Based Techniques have emerged as a significant player, capturing the interest of healthcare providers owing to their ease of use and rapid results.

As technology evolves, growth trends indicate that Assay-Based Techniques are witnessing the fastest growth, driven by an increasing demand for quick and reliable testing methods in clinical settings. Factors such as the rise in transfusion medicine, regulatory approvals for new assay technologies, and continuous advancements in biotech are propelling the adoption of these techniques, thereby influencing market dynamics across the board.

PCR-based and Microarray Technique (Dominant) vs. Assay-Based Techniques (Emerging)

PCR-based and Microarray Technique stands out as the dominant force in the segment, characterized by its high precision and capability to handle complex assays efficiently. This technique is primarily utilized in laboratories for detailed blood typing, making it essential in transfusion practices. Its reliable performance leads to widespread adoption among healthcare professionals. Conversely, Assay-Based Techniques represent an emerging segment that is quickly gaining traction. These techniques are recognized for their simplicity, rapid execution, and ability to deliver results at a lower cost, which resonates with the growing demand for accessible testing methods in various healthcare settings. The competition between these segments highlights the evolving preferences within the market, hinting at a shift towards more user-friendly and expedited testing solutions.

### By Test Type: Blood Group and Phenotype (Largest) vs. Antibody Screening (Fastest-Growing)

The US blood grouping-reagents market exhibits a diverse distribution among its test types, with Blood Group and Phenotype leading in market share due to its essential role in transfusion medicine and organ transplantation. Antibody Screening, while smaller in share, is witnessing significant growth as more healthcare facilities adopt comprehensive screening methods to ensure patient safety and compatibility. The demand for accurate blood matching is driving investments in this area, promoting innovation and expansion.

Growth trends reveal a strong push towards automation and technological advancements in testing methods, enhancing efficiency and reliability. The increasing prevalence of blood transfusions and surgical procedures is further propelling the market forward. Regulatory standards and rising awareness concerning safety and compatibility are key drivers contributing to the rapid development and acceptance of Antibody Screening tests, positioning it as the fastest-growing segment in the market.

Blood Group and Phenotype (Dominant) vs. Antibody Screening (Emerging)

Blood Group and Phenotype testing stands as the dominant segment within the US blood grouping-reagents market, characterized by its robust methodologies and critical importance in matching donors to recipients during transfusions. This segment operates with established techniques such as ABO and Rh typing, ensuring safe blood transfusion practices. In contrast, Antibody Screening is emerging as a vital component, incorporating advanced technologies to detect unexpected antibodies that could cause transfusion reactions. With a focus on enhancing patient safety, Antibody Screening is increasingly integrated into routine blood testing protocols, driven by the growing need for precise and prompt compatibility assessments, establishing itself as a key player in the evolving landscape of blood grouping reagents.

### By End User: Hospitals (Largest) vs. Blood Banks (Fastest-Growing)

In the US blood grouping-reagents market, hospitals hold the largest share, showcasing their critical role in patient care and diagnostic processes. This significant market presence can be attributed to the increasing number of hospital admissions and the rising prevalence of blood-related disorders, escalating the demand for blood grouping reagents in these healthcare facilities. Conversely, blood banks, while smaller in total market share, are experiencing rapid growth as they adapt to modern technologies and changing blood storage needs.

The growth trends for the end-user segment reveal a robust shift towards automation and efficiency, primarily driven by the need for quicker diagnostic results and greater accuracy in blood grouping. Clinical laboratories are also evolving to enhance their testing capabilities, which complements the needs of hospitals and blood banks alike. These facilities invest in advanced reagents and technologies, promoting more efficient blood typing and cross-matching processes, thereby supporting the overall market expansion.

Hospitals: Dominant vs. Blood Banks: Emerging

Hospitals operate as the dominant force within the US blood grouping-reagents market due to their extensive patient base and critical requirement for timely blood typing services. They depend heavily on a steady supply of reagents to ensure proper transfusions and compatibility testing, making them key customers in this landscape. Blood banks, although emerging, have begun capitalizing on new technologies and regulatory changes that enhance their operational efficiency and inventory management. Their role in blood storage and distribution is evolving, leading to improved collaboration with hospitals and clinical laboratories as they respond to the increasing demand for blood products.

## Competitive Benchmarking

The blood grouping-reagents market is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and technological advancements. Key players such as Abbott Laboratories (US), Thermo Fisher Scientific (US), and Bio-Rad Laboratories (US) are at the forefront, leveraging their extensive research capabilities and product portfolios to enhance their market positions. Abbott Laboratories (US) focuses on developing advanced diagnostic solutions, while Thermo Fisher Scientific (US) emphasizes its commitment to innovation through continuous product development and strategic acquisitions. Bio-Rad Laboratories (US) is also notable for its investment in R&D, which allows it to introduce cutting-edge reagents that meet evolving customer needs. Collectively, these strategies foster a dynamic competitive environment, driving growth and enhancing the overall market landscape.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market structure appears moderately fragmented, with several key players holding substantial market shares. This fragmentation allows for a diverse range of products and services, while the collective influence of these major companies shapes market trends and customer preferences.
In October Abbott Laboratories (US) announced the launch of a new line of blood grouping reagents designed to improve accuracy and speed in blood typing. This strategic move is significant as it not only reinforces Abbott's commitment to innovation but also positions the company to capture a larger share of the growing demand for rapid diagnostic solutions in clinical settings. The introduction of these reagents is expected to enhance operational efficiencies for laboratories, thereby solidifying Abbott's competitive edge.
In September Thermo Fisher Scientific (US) expanded its product offerings by acquiring a small biotech firm specializing in blood typing technologies. This acquisition is indicative of Thermo Fisher's strategy to bolster its capabilities in the blood grouping-reagents segment, allowing it to integrate advanced technologies into its existing product lines. Such strategic actions are likely to enhance the company's market presence and provide customers with more comprehensive solutions.
In August Bio-Rad Laboratories (US) entered into a partnership with a leading healthcare provider to develop customized blood grouping reagents tailored to specific patient populations. This collaboration highlights Bio-Rad's focus on personalized medicine and its ability to adapt to the unique needs of healthcare providers. By aligning its product development with the demands of the market, Bio-Rad is positioning itself as a leader in innovation within the blood grouping-reagents sector.
As of November current competitive trends indicate a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence (AI) in product development and operational processes. Strategic alliances are increasingly shaping the landscape, enabling companies to pool resources and expertise to drive innovation. Looking ahead, it is anticipated that competitive differentiation will evolve, with a shift from price-based competition to a focus on technological advancements, innovation, and supply chain reliability. This transition underscores the importance of agility and responsiveness in meeting the changing demands of the market.

## Recent News & Developments

The US Blood Grouping Reagents Market has seen significant developments recently, with companies such as Abbott Laboratories, Grifols, and Siemens Healthineers advancing their product lines to enhance blood compatibility testing. In September 2023, Eton Bioscience launched a new line of reagents aimed at improving efficiency in blood type determination, reflecting a broader trend towards automation and rapid testing in laboratories. Additionally, BioRad Laboratories and Thermo Fisher Scientific are collaborating on innovative solutions to streamline blood grouping processes.

In terms of mergers and acquisitions, Beckman Coulter's acquisition of a smaller diagnostics firm in August 2023 to expand its reagent offerings marks a notable trend in market consolidation driven by the demand for comprehensive testing solutions. Furthermore, the valuation of companies in this sector has improved markedly, with a growth projection supported by the rise in blood transfusion procedures and the increasing prevalence of blood-related disorders.

Recent statistics from the US Food and Drug Administration suggest a steady increase in the use of blood grouping reagents, further weighing in favor of sustained workforce investments and Research and Development efforts in the coming years, reflecting the robust market dynamics.

## Report Scope

| MARKET SIZE 2024 | 0.584(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 0.628(USD Million) |
| MARKET SIZE 2035 | 1.3(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.51% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Abbott Laboratories (US), Thermo Fisher Scientific (US), Siemens Healthineers (DE), Bio-Rad Laboratories (US), Ortho Clinical Diagnostics (US), Grifols (ES), Beckman Coulter (US), Merck KGaA (DE), F. Hoffmann-La Roche (CH) |
| Segments Covered | Product, Technique, Test Type, End User |
| Key Market Opportunities | Advancements in automation and precision diagnostics enhance efficiency in the blood grouping-reagents market. |
| Key Market Dynamics | Rising demand for advanced blood grouping reagents driven by regulatory changes and technological innovations in diagnostics. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What was the market valuation of the US blood grouping-reagents market in 2024?**
A: The market valuation was $0.584 Million in 2024.

**Q: What is the projected market valuation for the US blood grouping-reagents market by 2035?**
A: The projected valuation for 2035 is $1.3 Million.

**Q: What is the expected CAGR for the US blood grouping-reagents market during the forecast period 2025 - 2035?**
A: The expected CAGR is 7.51% during the forecast period 2025 - 2035.

**Q: Which companies are considered key players in the US blood grouping-reagents market?**
A: Key players include Abbott Laboratories, Thermo Fisher Scientific, Siemens Healthineers, and others.

**Q: What are the main product segments in the US blood grouping-reagents market?**
A: The main product segments are consumables and instruments.

**Q: How did the consumables segment perform in 2024?**
A: The consumables segment was valued between $0.35 Million and $0.8 Million in 2024.

**Q: What techniques are utilized in the US blood grouping-reagents market?**
A: Techniques include PCR-based, assay-based, massively parallel sequencing, and serology.

**Q: What was the valuation range for serology techniques in 2024?**
A: The valuation range for serology techniques was between $0.2 Million and $0.4 Million in 2024.

**Q: Which end users dominate the US blood grouping-reagents market?**
A: Dominant end users include hospitals, blood banks, and clinical laboratories.

**Q: What was the valuation for hospitals as end users in 2024?**
A: The valuation for hospitals as end users was between $0.292 Million and $0.65 Million in 2024.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-blood-grouping-reagents-market-13872*